Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
Discussing whether a new $487M investment from the government will help speed up the production of the most important va...
Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 07:42:13 25 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 07:42:14 25 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/25/2009 7:45:08 AM

RSS FEED

» Help

Current DateTime: 07:42:15 25 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size
Apr.17
9:51 AM ET
Friday, 17 Apr 2009
Analyst Eats Dendreon Crow

CNBC.com

As late as the day before the positive Dendreon data on its prostate cancer treatment Provenge came out, biotech analyst Jonathan Aschoff at Brean Murray Carret & Co. reiterated his "Sell" rating and $1 price target on the stock in a research note to clients.

Today he's offering a bit of a mea culpa.

Aschoff is upgrading DNDN from "Sell" to "Hold." But that's not all. Under normal circumstances I lift only brief quotes from analyst research notes for the blog or for my on-air reports. But since this one is relatively short and I know Dendreonians are gonna have a field day with this, I'm putting the whole thing on the blog.

"After more careful consideration of Dendreon's conference call, we are upgrading Dendreon to Hold from Sell due to our belief that management's bullish account of the data, despite the absence of any data presentation, will likely be justified by the data to come at the AUA conference on April 28. We find it increasingly difficult to believe that management would be that positive in a public forum, and therefore risk certain prosecution, by underdelivering at AUA due to their analyses being less than prospectively defined. We believe that Dendreon shares have an equal chance of rising or trading sideways, but we no longer see much risk of shares trading sharply lower upon presentation of the data. We also believe that there is far too much popular support for Provenge for the FDA to easily reneg on its SPA and the promise of approval should IMPACT succeed, as prospectively defined. Given the earlier results, we cannot explain how IMPACT succeeded, but we know that it does not matter as long as success was measured in a prospectively defined manner."

Wow.

Aschoff now says that his price target is "NA" or not applicable. In other words, he did not set a new one. BMC makes a market in DNDN [DNDN  Loading...      ()   ]and would like to bank the company.

Yeah, good luck with that.

SPA, by the way, is not a place where the FDA pampers itself. It stands for special protocol assessment which is basically an agreed-upon roadmap between the agency and a company on how to possibly win approval of a drug. IMPACT is the acronym for the Provenge study. And AUA is the American Urological Association.

What I think Aschoff is referring to is DNDN CEO Dr. Mitch Gold's repeated use of the word "unambiguous" to describe the test results. He said it on the conference call and again later in my interview with him on CNBC. He also called the data "a clear hit." I tried to pin him down on whether that meant they had met or surpassed the pre-defined threshold of showing at least a 22 percent reduction in the risk of death, but he wouldn't go there. That information will come out at AUA on the 28th.

I'll be reporting live from that meeting in Chicago where I also hope to interview Dr. Gold again shortly after researchers present the data.

Questions?  Comments?  and follow me on Twitter at mhuckman

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 05:21:40 25 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:04:04 25 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 02:05:47 25 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:01:48 25 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters